Fas ligand (FasL) not only induces apoptosis in Fas receptor-bearing target cells, it is also able to transmit signals into the FasL-expressing cell via its intracellular domain (ICD).
IntroductionFas ligand (FasL, CD95L, CD178, TNSF6) is a 40-kDa glycosylated type II transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Its extracellular portion harbors a C-terminal TNF homology domain that assembles as homotrimers and mediates interactions with receptors. Interestingly, the 77-amino acid (aa)-long N-terminal mouse FasL intracellular domain (ICD) contains several conserved signaling motifs, such as a tandem casein kinase I phosphorylation site (aa 17-21), a proline-rich domain (PRD; aa 45-69) that serves as a docking site for SH3 domain-containing proteins, and a tyrosine phosphorylation site located at aa 7. 1 The FasL/Fas receptor system is renowned as a potent inducer of apoptosis in the receptor-bearing cell and is especially important for numerous immune system functions, including removal of target cells by natural killer and cytotoxic T cells, (self) elimination of effector cells after the proliferative phase of an immune response (activation-induced cell death), and maintenance of immuneprivileged sites. 2,3 Naturally occurring homozygous mutations of the Fas (lpr) and the FasL (gld) genes, which abolish Fas-mediated apoptosis, lead to development of a severe lymphoproliferative disease. 4 Because of its potent proapoptotic potential and important function, expression and activity of FasL is tightly regulated at transcriptional and posttranslational levels and is restricted to a few cell types, such as immune effector cells and cells of immuneprivileged sites (eg, eyes, testis, brain). In contrast, the Fas receptor is expressed in a wide variety of tissues, including the lymphoid tissues, liver, heart, and ovary. 1,5 In addition to its pro-death function, the Fas/FasL system also transduces nonapoptotic signals into the Fas-expressing cells. Among others, Fas is required for cell survival, proliferation and activation of T cells, liver regeneration, and neurogenesis. 6,7 A number of studies have presented evidence for alternative signal transduction via "reverse signaling" into the FasL-bearing cells, although conflicting data have been published regarding the functional implications (for review see Voss et al 1 ). First evidence The online version of this article contains a data supplement.The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked ''advertisement'' in accordance with 18 USC section 1734. For personal use only. on May 8, 2018. by guest www.bloodjournal.org From for the existence of retrograde FasL signaling stems from 2 studies that demonstrated either costimulation of murine CD8 ϩ cytotoxic T lymphocyte (CTL) cell lines upon FasL cross-linking 8 or inhibition of activation-induced proliferation in murine CD4 ϩ T cells. 9 In both cases, FasL reverse signaling could...